Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lifecore Biomedical (LFCR) Equity Average: 2011-2025

Historic Equity Average for Lifecore Biomedical (LFCR) over the last 14 years, with May 2025 value amounting to $1.8 million.

  • Lifecore Biomedical's Equity Average fell 87.71% to $1.8 million in Q2 2025 from the same period last year, while for May 2025 it was $1.8 million, marking a year-over-year decrease of 87.71%. This contributed to the annual value of $6.3 million for FY2025, which is 78.56% up from last year.
  • According to the latest figures from Q2 2025, Lifecore Biomedical's Equity Average is $1.8 million, which was down 79.83% from $8.8 million recorded in Q1 2025.
  • Over the past 5 years, Lifecore Biomedical's Equity Average peaked at $205.1 million during Q1 2021, and registered a low of -$8.9 million during Q3 2023.
  • Its 3-year average for Equity Average is $9.8 million, with a median of $7.3 million in 2024.
  • Its Equity Average has fluctuated over the past 5 years, first tumbled by 110.74% in 2023, then spiked by 194.83% in 2024.
  • Lifecore Biomedical's Equity Average (Quarterly) stood at $174.3 million in 2021, then tumbled by 57.25% to $74.5 million in 2022, then crashed by 108.15% to -$6.1 million in 2023, then spiked by 194.83% to $5.8 million in 2024, then slumped by 87.71% to $1.8 million in 2025.
  • Its Equity Average stands at $1.8 million for Q2 2025, versus $8.8 million for Q1 2025 and $5.8 million for Q4 2024.